Alfuzosin
- Generic Name
- Alfuzosin
- Brand Names
- Uroxatral, Xatral
- Drug Type
- Small Molecule
- Chemical Formula
- C19H27N5O4
- CAS Number
- 81403-80-7
- Unique Ingredient Identifier
- 90347YTW5F
- Background
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.
- Indication
Alfuzosin is used to treat the signs and symptoms of benign prostatic hyperplasia (BPH).
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH)
- Associated Therapies
- -
Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study
- Conditions
- Prostatic Diseases
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 118
- Registration Number
- NCT00575913
- Locations
- 🇹🇭
Sanofi-Aventis, Bangkok, Thailand
Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 172
- Registration Number
- NCT00549939
- Locations
- 🇷🇺
Sanofi-Aventis Aministrative Office, Moscow, Russian Federation
🇹🇷Sanofi-Aventis Administrative Office, Istanbul, Turkey
Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy
- Conditions
- BPH/LUTS/Sexual Functions
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2007-10-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 166
- Registration Number
- NCT00542165
- Locations
- 🇰🇷
Sanofi-Aventis, Seoul, Korea, Republic of
The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score
- Conditions
- Benign Prostatic Hyperplasia
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2007-10-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 372
- Registration Number
- NCT00540891
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2009-09-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 431
- Registration Number
- NCT00486785
- Locations
- 🇲🇽
Sanofi-Aventis, Mexico, Mexico
Alfuzosin Hydrochloride to Relieve Ureteral Stent Discomfort
- Conditions
- Ureteral Stent Discomfort
- First Posted Date
- 2007-04-30
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 60
- Registration Number
- NCT00467467
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
ALF-STONE: Alfuzosin in Uretheric Stones
- Conditions
- Prostatic Hyperplasia
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2007-09-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 220
- Registration Number
- NCT00454402
- Locations
- 🇵🇹
Sanofi-Aventis, Lisbon, Portugal
Alfuzosin Versus Placebo in Acute Urinary Retention
- Conditions
- Urinary Retention
- First Posted Date
- 2007-03-29
- Last Posted Date
- 2007-08-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 160
- Registration Number
- NCT00453908
- Locations
- 🇩🇰
Sanofi-Aventis, Hoersholm, Denmark
The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones
- Conditions
- Renal Colic
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2012-07-12
- Lead Sponsor
- Soroka University Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT00451061
- Locations
- 🇮🇱
Urology department, Soroka university medical center, Beer-Sheva, p,o,box 151, Israel
Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study
- Conditions
- Prostatic Hyperplasia
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT00427882
- Locations
- 🇰🇷
Handok, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.